New HCPCS Code for Portrazza® (necitumumab)

Effective January 1, 2017 there is a a product‐specific Healthcare Common Procedure Coding System (HCPCS) code forPortrazza® (necitumumab) for injection.

The new code, J9295, is defined as “injection, necitumumab, 1 mg.” This code is effective January 1, 2017. 

2017 Highlights of ASH Series – Registration Open!

Registration is now open for the 2017 Highlights of ASH in North America series. 

As a partner in this event WSMOS is pleased to announce that WSMOS members are entitled to receive discounted registration (to the ASH Member rate). 

If you were unable to make it to this year’s ASH Annual Meeting, attend one of five Highlights programs throughout the US to hear a comprehensive review of the latest scientific findings and treatment strategies that was presented in San Diego earlier this month! 

Click on the link below for registration and program information.  The 2017 Highlights of ASH in North America series will take place in the following locations:

·         Highlights of ASH in North America

o    January 13-14:  Atlanta

o    January 20-21:  Chicago and Dallas

o    January 27-28:  New York and Seattle


New FDA Approval for Genentech's TECENTRIQ®

Genentech is excited to share the news of a new FDA approval. TECENTRIQ® (atezolizumab) is NOW FDA APPROVED for the treatment of patients with previously treated metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ.

Click Here for the full Prescribing Information.

Click Here for more information including NDC and ICD-10 codes. 

New Labeling Approved for XTANDI

On October 21, 2016, Astellas Pharma Inc. and Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide compared to patients who were treated with bicalutamide.

Click Here for the XTANDI Clinical Launch Announcement. 

New FDA approval for LARTRUVO™ (olaratumab)

On October 19, 2016, the US Food and Drug Administration (FDA) approved LARTRUVO™ (olaratumab) injection, 10 mg/mL solution. LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.

This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

Click here for full Prescribing Information and see below for Important Safety Information for LARTRUVO.

KEYTRUDA Receives New Approval for mNSCLC

Merck is pleased to announce that KEYTRUDA is now the only anti–PD-1 approved for first-line treatment of mNSCLC with high PD-L1 expression (TPS ≥50%). In the KEYNOTE-024 study, KEYTRUDA demonstrated superior survival in the first-line treatment  of mNSCLC vs platinum-containing chemotherapy in patients whose tumors expressed high levels of PD-L1 (TPS ≥50%).

For more information:

Click Here to read the Press Release

Click Here to read the Announcement Letter

KEYTRUDA Prescribing Information

KEYTRUDA Medication Guide

CMS Assigns Unique C-code to TECENTRIQ™

A unique C-code that was recently assigned to TECENTRIQ™ (atezolizumab) by the Centers for Medicare & Medicaid Services (CMS). The C-code for TECENTRIQ is C9483 (Injection, atezolizumab, 10 mg).
The unique C-code goes into effect on October 1, 2016. Payers may require its use until a permanent J-code is assigned. The permanent J-code is expected to be available for use starting on January 1, 2018.
The C-code is used primarily in the Medicare hospital outpatient setting. However, some payers accept this C-code instead of unclassified J- or C-codes when billing for TECENTRIQ. Please check with your payers to verify codes and special billing requirements.

Click Here for the TECENTRIQ Billing and Coding Flash Card which contains additional information about coding and billing. Click Here for the full TECENTRIQ Prescribing Information. Dedicated Specialists at TECENTRIQ Access Solutions can be reached at (888) 249‐4918, or visit for more information.

Taiho Patient & Reimbursement Assistance Programs

Taiho Oncology Patient Support offers the following services: 

• Co-pay support for eligible, privately insured patients. Such patients can receive a Taiho Oncology Patient Support Co-pay Card for help with out-of-pocket expenses. 

• Patient Assistance Program. Taiho Patient Support will research financial assistance options for patients with no insurance coverage, insuffi­cient prescription coverage, or insufficient resources to pay for treatment with Lonsurf. Eligible patients may receive Lonsurf at no cost based on assistance, financial, and medical criteria. 

• Alternate funding support. Taiho Patient Support will also refer eligible, publicly insured patients to nonprofit founda­tions that may be able to offer them co-pay assistance.

Click Here for more information on these programs.